000839233 000__ 05980cam\a2200505Ii\4500
000839233 001__ 839233
000839233 005__ 20230306144718.0
000839233 006__ m\\\\\o\\d\\\\\\\\
000839233 007__ cr\un\nnnunnun
000839233 008__ 180514s2018\\\\si\a\\\\o\\\\\000\0\eng\d
000839233 019__ $$a1036268798$$a1037026321$$a1040653787
000839233 020__ $$a9789811070136$$q(electronic book)
000839233 020__ $$a981107013X$$q(electronic book)
000839233 020__ $$z9789811070129
000839233 020__ $$z9811070121
000839233 0247_ $$a10.1007/978-981-10-7013-6$$2doi
000839233 035__ $$aSP(OCoLC)on1035558289
000839233 035__ $$aSP(OCoLC)1035558289$$z(OCoLC)1036268798$$z(OCoLC)1037026321$$z(OCoLC)1040653787
000839233 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dN$T$$dEBLCP$$dYDX$$dAZU$$dUAB$$dOCLCF$$dOCLCQ
000839233 049__ $$aISEA
000839233 050_4 $$aRC280.P7
000839233 08204 $$a616.99/463061$$223
000839233 24500 $$aHormone therapy and castration resistance of prostate cancer /$$cYoichi Arai, Osamu Ogawa, editors.
000839233 264_1 $$aSingapore :$$bSpringer,$$c2018.
000839233 300__ $$a1 online resource (viii, 433 pages) :$$billustrations (some color)
000839233 336__ $$atext$$btxt$$2rdacontent
000839233 337__ $$acomputer$$bc$$2rdamedia
000839233 338__ $$aonline resource$$bcr$$2rdacarrier
000839233 347__ $$atext file$$bPDF$$2rda
000839233 5050_ $$aIntro; Contents; 1: Introduction; 2: Recent Trends in Hormone Therapy for Prostate Cancer in Japan; 2.1 Introduction; 2.2 Source of Data; 2.3 Trend in Hormonal Therapy as Main Treatment; 2.3.1 Initial Treatment Patterns in Japan; 2.3.2 Treatment Pattern Difference Between Japan and the USA; 2.3.3 Types of Hormonal Therapy in Japan; 2.3.4 Types of Castration; 2.3.5 Types of Antiandrogen; Reference; 3: Risk Assessment Among Patients Receiving Primary ADT for Prostate Cancer; 3.1 TNM Classification; 3.2 J-CAPRA Score; 3.3 Risk Assessment in the Next Generation; References
000839233 5058_ $$a4: Patient-Derived Xenografts for Research on Hormonal Therapy of Prostate Cancer4.1 Introduction; 4.2 Establishment of Prostate Cancer Patient-Derived Xenograft Models; 4.3 Basic and Clinical Application of PDX Models for Understanding Resistance to Hormonal Therapy; 4.4 Future Perspectives; References; 5: Impact of GnRH Antagonist and LHRH Agonist on the Gonadal Axis; 5.1 Impact of GnRH Antagonist and LHRH Agonist on the Gonadal Axis; 5.1.1 First Impact: Discovery of LHRH Agonist; 5.1.2 Second Impact: New Hope, GnRH Antagonist
000839233 5058_ $$a5.1.3 Relationship Between LHRH Agonist and Adrenal Androgen5.1.4 The Effect of Antagonist on Adrenal Androgen; References; 6: Controversies on Combined Androgen Blockade for Prostate Cancer; References; 7: Adrenal Androgen in Prostate Cancer; 7.1 Introduction; 7.2 Evaluation of Prostate Androgen Concentration by Highly Sensitive Quantitative Analysis; 7.3 Hormone Metabolism in the Prostate; 7.4 Role of Adrenal-Derived Androgens in PCa; References; 8: Intermittent ADT for Prostate Cancer; 8.1 Introduction; 8.2 Concept of Intermittent ADT; 8.3 Intermittent ADT in Animal Models
000839233 5058_ $$a8.4 Clinical Experiences of Intermittent ADT8.5 Randomized Controlled Trials and Meta-analyses/Systematic Reviews Comparing Intermittent Versus Continuous ADT; 8.6 Clinical Guidelines Concerning Intermittent ADT; 8.7 Methods of Intermittent ADT; 8.8 Advantages and Disadvantages of Intermittent ADT; 8.9 Future Directions for Intermittent ADT; References; 9: Prognostic Significance of Monitoring Serum Testosterone in Primary ADT for Prostate Cancer; 9.1 Introduction; 9.2 The Significance of Lower Testosterone Level Below 50 ng/dL
000839233 5058_ $$a9.3 The Difference in Clinical Outcome Between GnRH Antagonist and LHRH Agonist9.4 Intratumoral Androgen Synthesis; 9.5 Significance of TST Suppression at Early Stage of Prostate Cancer; 9.6 Future Directions; References; 10: Ethnic Variation in Clinical Outcomes of Hormone Therapy for Prostate Cancer; 10.1 Introduction; 10.2 Impact of Ethnicity on the Survival of Men with Prostate Cancer in the United States; 10.3 Comparison of Clinical Outcome of Prostate Cancer Among Various Ethnics in Hawaii; 10.3.1 Comparison of Clinical Outcome Between Caucasians and Japanese
000839233 506__ $$aAccess limited to authorized users.
000839233 520__ $$aThis comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
000839233 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed May 14, 2018).
000839233 650_0 $$aProstate$$xCancer$$xHormone therapy.
000839233 7001_ $$aArai, Yoichi,$$eeditor.
000839233 7001_ $$aOgawa, Osamu,$$eeditor.
000839233 77608 $$iPrint version: $$z9811070121$$z9789811070129$$w(OCoLC)1005115930
000839233 852__ $$bebk
000839233 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-981-10-7013-6$$zOnline Access$$91397441.1
000839233 909CO $$ooai:library.usi.edu:839233$$pGLOBAL_SET
000839233 980__ $$aEBOOK
000839233 980__ $$aBIB
000839233 982__ $$aEbook
000839233 983__ $$aOnline
000839233 994__ $$a92$$bISE